Dichloroacetate, a pyruvate dehydrogenase activator, alleviates high‐fat‐induced impairment of myogenic differentiation in skeletal muscles
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.14102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Chuang-Yen Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Dichloroacetic Acid, Diet, High-Fat, Mice, Inbred C57BL, Muscle, Skeletal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of National Defense-Medical Affairs Bureau, Tri-Service General Hospital, Penghu Branch.
Abstract (Originalsprache)
Obesity‐induced impairment of myogenic differentiation leads to muscle loss and sarcopenia. Pyruvate dehydrogenase (PDH) plays a crucial role in glucose metabolism and is associated with muscle differentiation. However, the effect of dichloroacetate (DCA), a PDH activator, on obesity‐induced impairment of myogenic differentiation remains unknown. Here, we evaluated the effects of DCA treatment on high‐fat intake‐induced impairment of myogenic differentiation in C2C12 cells and C57BL/6 mice. In C2C12 cells, DCA treatment improved PDH activity that was reduced by palmitate (PAL) and decreased the lactate concentrations in the media. Additionally, DCA reversed PAL‐ and high‐fat diet (HFD)‐induced decrease in the expression of myoblast determination protein 1 (MyoD), myogenin (MyoG) and myosin heavy chain (MyHC) in C2C12 cells and C57BL/6 mice. To explore the possible mechanism, DCA treatment restored the levels of p‐Akt, p‐FoxO1, p‐FoxO3a and p‐p38 MAPK levels in PAL‐treated C2C12 cells. Moreover, the protective effects of DCA were reversed by treatment with the Akt inhibitor MK2206 in C2C12 cells. In summary, DCA treatment alleviated high‐fat intake‐induced impairment of myogenic differentiation via Akt signalling, suggesting its potential in treating obesity‐associated muscle loss and sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
- Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan.
- Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan.
ORCID-Profile: Hung-Che Chien
Förderung
- Ministry of National Defense-Medical Affairs Bureau
- Tri-Service General Hospital, Penghu Branch
Zitieren
APA
Huang, C. Y., Han, I. S., Hsieh, P. S., Tsai, M. C., & Chien, H. C. (2025). Dichloroacetate, a pyruvate dehydrogenase activator, alleviates high‐fat‐induced impairment of myogenic differentiation in skeletal muscles. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14102
Vancouver
Huang CY, Han IS, Hsieh PS, Tsai MC, Chien HC. Dichloroacetate, a pyruvate dehydrogenase activator, alleviates high‐fat‐induced impairment of myogenic differentiation in skeletal muscles. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.14102
BibTeX
@article{Huang2025,
author = {Huang, Chuang-Yen and Han, I-Shan and Hsieh, Po-Shiuan and Tsai, Min-Chien and Chien, Hung-Che},
title = {Dichloroacetate, a pyruvate dehydrogenase activator, alleviates high‐fat‐induced impairment of myogenic differentiation in skeletal muscles},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.14102}
}
EUVIMED